References
Koller G, Cusnir I, Hall J, Ye C ( 2019 ) Reversible alopecia areata: a little known side effect of leflunomide. Clin Rheumatol. 38(7):2015–2016. doi: https://doi.org/10.1007/s10067-019-04577-3. [Epub ahead of print]
Tosti A, Misciali C, Piraccini BM, Peluso AM, Bardazzi F (1994) Drug-induced hair loss and hair growth. Drug Saf 10(4):310–317
Flanagan K, Sperling L, Lin J (2019) Drug-induced alopecia after dupilumab therapy. JAAD Case Rep 5(1):54–56
Lakhmiri M, Cavelier-Balloy B, Lacoste C, Cassius C, Baroudjian B, Delyon J, Lebbé C, Reygagne P (2018) Nivolumab-induced alopecia areata: a reversible factor of good prognosis? JAAD Case Rep 4(8):761–765
Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, Cohen JD, Coquerelle P, Goujon E, Jullien D, Brixi H (2014) Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 70(6):1146–1149
Hammerschmidt M, Mulinari Brenner F (2014) Efficacy and safety of methotrexate in alopecia areata. An Bras Dermatol 89(5):729–734
Sardana K, Gupta A, Gautam RK (2018) Recalcitrant alopecia areata responsive to leflunomide and anthralin—potentially undiscovered JAK/STAT inhibitors? Pediatr Dermatol 35:856–858
Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, de Jong A, Harel S, DeStefano GM, Rothman L, Singh P, Petukhova L, Mackay-Wiggan J, Christiano AM, Clynes R (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043–1049
Kraan MC, Smeets TJ, van Loon MJ, Breedveld FC, Dijkmans BA, Tak PP (2004) Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 63:1056–1061
Cao WW, Kao PN, Aoki Y, Xu JC, Shorthouse RA, Morris RE (1996) A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-beta 1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 28:3079–3080
Fragoso YD, Brooks JB (2015) Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 8:315–320
Marijnen Y, de Korte D, Haverkort W et al (1989) Studies on the incorporation of precursors into purine and pyrimidine nucleotides via “de novo” and “salvage” pathways in normal lymphocytes and lymphoblastic cell-line cells. Biochim Biophys Acta 1012:148–155
McElwee KJ (1999) Third international research workshop on alopecia Areata. J Invest Dermatol 112(5):822–824
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
None.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
See related article, https://doi.org/10.1007/s10067-019-04689-w
Rights and permissions
About this article
Cite this article
Sardana, K., Gupta, A. & Gupta, P.K. Leflunomide: an unlikely trigger and mechanistically a beneficial drug for alopecia areata. Clin Rheumatol 38, 2957–2958 (2019). https://doi.org/10.1007/s10067-019-04669-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-019-04669-0